Ignite Creation Date:
2024-05-05 @ 9:23 PM
Last Modification Date:
2024-10-26 @ 10:04 AM
Study NCT ID:
NCT00879177
Status:
COMPLETED
Last Update Posted:
2017-04-10
First Post:
2009-03-24
Brief Title:
Smoking Study With Behavioral Therapy for Hypertensive Patients
Sponsor:
UConn Health
Organization:
UConn Health
Study Overview
Official Title:
Contingency Management for Initiating Smoking Abstinence in Patients With Hypertension
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VANQUISH
Brief Summary:
In total 260 patients with pre- and stage I hypertension who are regular smokers will be randomized to varenicline alone or varenicline plus behavioral therapy Patients in both conditions will receive varenicline titrated to a maximal dose of 10 mg twice daily for 12 weeks along with standard smoking cessation therapy and regular carbon monoxide CO and cotinine monitoring A significantly higher proportion of behavioral therapy patients are expected to achieve and maintain long durations of abstinence than patients receiving varenicline alone Clinic and 24-hour blood pressure BP and heart rate HR will be primary clinical outcomes The investigators expect that BP and HR will decrease more among behavioral therapy than non-behavioral therapy patients and reductions in smoking may mediate decreases in these indices
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01DA024667 | NIH | None | httpsreporternihgovquickSearchR01DA024667 |